Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COFBRO
- Development stage
- Unknown
- Lead developer
- Wellmed Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
COFBRO is a combination respiratory medication developed and marketed by Wellmed Pharma. It contains four active ingredients: terbutaline sulphate, a beta-2 adrenergic receptor agonist that acts as a bronchodilator; ambroxol hydrochloride, a mucolytic agent that thins mucus; guaiphenesin, an expectorant that increases the volume of airway secretions to facilitate their removal; and menthol, which provides a soothing effect. This formulation is designed as a small molecule combination therapy for treating respiratory conditions involving bronchospasm and mucus congestion, such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory tract disorders. It is typically administered as an oral syrup.
- Brand names
- COFBRO
02
Targets
ADRB1 (β1)ADRB2 (β2)ADRB3 (β3)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on COFBRO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COFBRO.